ISAR-TRIPLE: 6 weeks versus 6 months of clopidogrel in patients with oral anticoagulation and drug-eluting stent

There are a significant number of patients receiving drug-eluting stents and besides, require oral anticoagulation. The combination of anticoagulants, aspirin, and clopidogrel greatly increases the rate of bleeding, because of this, the time of the triple scheme should be as short as possible. 

The aim of this study was to compare the triple therapy for 6 weeks versus 6 months in patients with indications for oral anticoagulation who received drug-eluting stents. This study randomized 614 patients (307 in each group) at 3 centers in Europe. In 85% of cases, an indication of anticoagulation was for atrial fibrillation. The primary endpoint (composite of death, myocardial infarction, definite thrombosis, stroke, and major bleeding) at 9 months was 9.8% versus 8.8% in the group of 6 weeks and 6 months, respectively. No difference was observed when observing major bleeding separately (5.3% versus 4%, P = 0.44). 

Conclusion 

Triple therapy for 6 weeks was not superior to triple therapy for 6 months after implantation of a drug-eluting stent in relation to clinical events. Reducing time of triple therapy did not reduce bleeding or increase the incidence of ischemic events. 

2_nikolaus_sarafoff
Nikolaus Sarafoff
2014-09-16

Original title: A Prospective, Randomized Trial of Six Weeks Versus Six Months of Clopidogrel in Patients Treated with Concomitant Aspirin and Oral Anticoagulant Therapy Following Coronary Drug-Eluting Stent Implantation.

More articles by this author

OPTIMIZE: 3 months versus 12 months of dual anti-aggregation with zotarolimus-eluting stents

The current recommendation for dual anti-aggregation post-DES implantation is 12 months. However, the ideal length for specific types of stents is unclear. This study...

SECURITY: 6 months versus 12 months of dual anti-aggregation using 2nd generation DES

This multicenter noninferiority design work included 1399 patients randomized to receive 6 months (n = 682) versus 1 year (n = 717) dual anti-aggregation...

VELOCITY: Peritoneal hypothermia in patients undergoing primary angioplasty

There are clinics hypothesis that systemic hypothermia (≤34.9) could reduce infarct size if set before reperfusion. Peritoneal lavage had a well-established safety profile and...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | ALL-RISE Trial: Coronary Physiological Assessment Using FFRangio

Coronary physiological assessment using pressure-wire techniques (FFR/iFR) carries a Class IA recommendation in ACC/AHA guidelines; however, its use remains limited due to factors such...

ACC 2026 | Protect The Head-To-Head Trial: Randomized Comparison Between Emboliner and Sentinel During TAVI

Ischemic stroke remains one of the most feared complications of TAVI, with a relatively low but persistent incidence of 2–4%, without significant reduction over...

ACC 2026 | PRO-TAVI Trial: Deferring Coronary Angioplasty in Patients Undergoing TAVI

Coronary artery disease is common in patients with severe aortic stenosis undergoing TAVI. Current guidelines recommend considering revascularization in significant coronary lesions, particularly in...